MLN-576 | XR-11576 | CAS#346689-77-8 | Topoisomerase I&II Inhibitor

MedKoo Cat#: 527301 | Name: MLN-576

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MLN-576, also known as XR-11576, is a DNA topoisomerase I and II inhibitor used for the treatment of solid tumors.

Chemical Structure

MLN-576

CAS#346689-77-8

Theoretical Analysis

MedKoo Cat#: 527301

Name: MLN-576

CAS#: 346689-77-8

Chemical Formula: C23H24N4O2

Exact Mass: 388.1899

Molecular Weight: 388.47

Elemental Analysis: C, 71.11; H, 6.23; N, 14.42; O, 8.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

MLN-576; MLN 576; MLN576; XR-11576; XR 11576; XR11576

IUPAC/Chemical Name

(R)-N-(1-(dimethylamino)propan-2-yl)-4-methoxybenzo[a]phenazine-11-carboxamide

InChi Key

ACAXGYADTLFREX-CQSZACIVSA-N

InChi Code

InChI=1S/C23H24N4O2/c1-14(13-27(2)3)24-23(28)17-8-5-9-18-22(17)26-21-16-7-6-10-20(29-4)15(16)11-12-19(21)25-18/h5-12,14H,13H2,1-4H3,(H,24,28)/t14-/m1/s1

SMILES Code

O=C(C1=C2C(N=C3C=CC4=C(OC)C=CC=C4C3=N2)=CC=C1)N[C@H](C)CN(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 388.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jobson AG, Willmore E, Tilby MJ, Mistry P, Charlton P, Austin CA. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases. Cancer Chemother Pharmacol. 2009 Apr;63(5):889-901. doi: 10.1007/s00280-008-0812-9. PubMed PMID: 18679685. 2: Lewis LJ, Mistry P, Charlton PA, Thomas H, Coley HM. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anticancer Drugs. 2007 Feb;18(2):139-48. PubMed PMID: 17159600. 3: de Jonge MJ, Kaye S, Verweij J, Brock C, Reade S, Scurr M, van Doorn L, Verheij C, Loos W, Brindley C, Mistry P, Cooper M, Judson I. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. Br J Cancer. 2004 Oct 18;91(8):1459-65. PubMed PMID: 15452551; PubMed Central PMCID: PMC2409936. 4: Di Nicolantonio F, Knight LA, Di Palma S, Sharma S, Whitehouse PA, Mercer SJ, Charlton PA, Norris D, Cree IA. Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. Anticancer Drugs. 2004 Oct;15(9):849-60. PubMed PMID: 15457125. 5: Mistry P, Stewart AJ, Dangerfield W, Baker M, Liddle C, Bootle D, Kofler B, Laurie D, Denny WA, Baguley B, Charlton PA. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28. PubMed PMID: 11914637. 6: Wang S, Miller W, Milton J, Vicker N, Stewart A, Charlton P, Mistry P, Hardick D, Denny WA. Structure-activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576. Bioorg Med Chem Lett. 2002 Feb 11;12(3):415-8. PubMed PMID: 11814810. 7: Vicker N, Burgess L, Chuckowree IS, Dodd R, Folkes AJ, Hardick DJ, Hancox TC, Miller W, Milton J, Sohal S, Wang S, Wren SP, Charlton PA, Dangerfield W, Liddle C, Mistry P, Stewart AJ, Denny WA. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. J Med Chem. 2002 Jan 31;45(3):721-39. PubMed PMID: 11806724. 8: Moorthy NS, Pratheepa V, Ramos MJ, Vasconcelos V, Fernandes PA. Fused aryl-phenazines: scaffold for the development of bioactive molecules. Curr Drug Targets. 2014;15(7):681-8. Review. PubMed PMID: 24499398. 9: Lansiaux A, Bailly C. [Perspectives on the oncologist pharmacopoeia]. Bull Cancer. 2003 Jan;90(1):25-30. French. PubMed PMID: 12609801. 10: Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 2003;3(3):339-53. Review. PubMed PMID: 12570767.